Core Viewpoint - Investors are increasingly seeking growth stocks, particularly in the financial sector, to achieve above-average returns, but identifying such stocks involves significant risk and volatility [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score system aids in identifying promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - MasterCard (MA) is currently highlighted as a recommended growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth being particularly attractive [3] - MasterCard's historical EPS growth rate stands at 21.5%, with a projected EPS growth of 11.6% for the current year, surpassing the industry average of 11.3% [4] Group 3: Asset Utilization - The asset utilization ratio, or sales-to-total-assets (S/TA) ratio, is an important metric for assessing efficiency in generating sales [5] - MasterCard's S/TA ratio is 0.62, indicating that the company generates $0.62 in sales for every dollar in assets, compared to the industry average of 0.41 [5] Group 4: Sales Growth - Sales growth is another key indicator, with MasterCard expected to achieve a 15% sales growth this year, significantly higher than the industry average of 4.8% [6] Group 5: Earnings Estimate Revisions - Positive trends in earnings estimate revisions correlate strongly with stock price movements [7] - MasterCard's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate increasing by 1.9% over the past month [8] Group 6: Overall Positioning - MasterCard has achieved a Growth Score of B and a Zacks Rank of 2 due to positive earnings estimate revisions, positioning it well for potential outperformance [10]

MasterCard (MA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earni ...

Core Insights - American Express Company (AXP) has established a multi-year strategic partnership with Toast, Inc. to enhance hospitality experiences by integrating guest data from its restaurant reservation platforms into Toast's systems [1][2] - This partnership strengthens AXP's position in the restaurant and hospitality ecosystem, creating a seamless guest experience from reservation to payment [2][4] - AXP differentiates itself from competitors by linking card membership to exclusive, data-enhanced hospitality services, which can drive higher loyalty and spending among cardmembers [3][5] Company Strategy - The integration of Resy and Tock listings into Toast's platforms enhances visibility and marketing for restaurants, potentially improving retention and attracting more establishments to Toast [4][7] - AXP's approach allows it to deepen customer relationships and expand merchant acceptance, while Toast benefits from new traffic sources and tools [4][5] Competitive Advantage - AXP sets itself apart from Visa and Mastercard by integrating deeply into the hospitality journey, offering personalized dining experiences and creating value beyond transactions [5][6] - This end-to-end control reinforces AXP's premium image and positions it as a hospitality partner rather than just a payment processor [5][6] Financial Performance - AXP shares have declined 0.5% year-to-date, while the industry has grown by 2.3% [6] - AXP trades at a forward price-to-earnings ratio of 17.87, below the industry average of 20.89, with a Value Score of B [9] - The Zacks Consensus Estimate for AXP's 2025 earnings is $15.26 per share, indicating a 14.3% increase from the previous year [10][12]

MasterCard currently has an average brokerage recommendation (ABR) of 1.47, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 38 brokerage firms. An ABR of 1.47 approximates between Strong Buy and Buy. Of the 38 recommendations that derive the current ABR, 27 are Strong Buy and four are Buy. Strong Buy and Buy respectively account for 71.1% and 10.5% of all recommendations. The recommendations of Wall Street analysts are often re ...

NEW YORK, Aug. 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Flywire Corporation (NASDAQ: FLYW). Shareholders who purchased shares of FLYW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/flywire-corporation-loss-submission-form/?id=159957&from=4 CLASS PERIOD: February 2 ...

August 6, 2025 © 2025 Deluxe Corporation Brian Anderson Vice President, Strategy & Investor Relations 2 Today's Presenters Second Quarter 2025 Earnings Barry McCarthy President and Chief Executive Officer Chip Zint Senior Vice President and Chief Financial Officer Brian Anderson Vice President, Strategy & Investor Relations 3 Cautionary Statement Statements made in this presentation regarding Deluxe, the company's,or management's intentions, expectations, outlook, or predictions about future results or even ...

Core Insights - Global Payments Inc (GPN) reported second-quarter 2025 adjusted earnings per share (EPS) of $3.10, exceeding the Zacks Consensus Estimate of $3.03, with an 11% year-over-year increase [1][8] - Adjusted net revenues rose 2% year over year to $2.4 billion, slightly surpassing the consensus mark by 0.2% [1] - The strong performance was driven by growth in Merchant Solutions and Issuer Solutions, although elevated expenses partially offset the gains [1] GPN's Operating Performance - Adjusted operating income for the quarter was $1.1 billion, reflecting a 4.5% year-over-year increase [2] - Adjusted operating margin expanded by 130 basis points to 44.6% [2] - Total operating expenses increased by 2.3% year over year to $1.5 billion, primarily due to higher selling, general, and administrative expenses [2] Segmental Performances - **Merchant Solutions**: Adjusted revenues reached $1.8 billion, up 1.1% year over year, exceeding the Zacks Consensus Estimate by 0.7% [3] - Adjusted operating income for this segment increased by 3.7% year over year to $917.3 million, beating the consensus estimate of $902.5 million [3] - **Issuer Solutions**: Adjusted revenues were $547.4 million, growing 4% year over year and surpassing the Zacks Consensus Estimate by 1.1% [4] - Adjusted operating income improved by 8% year over year to $266.4 million, exceeding the consensus estimate of $255.7 million [4] GPN's Financial Position (As of June 30, 2025) - Cash and cash equivalents increased to $2.6 billion from $2.4 billion at the end of 2024 [5] - Total assets rose to $48.5 billion from $46.9 billion at the end of 2024 [5] - Long-term debt decreased to $14.2 billion from $15.1 billion at the end of 2024, with the current portion totaling $1.9 billion [5] - Total equity increased to $23.2 billion from $22.9 billion at the end of 2024 [5] Cash Flow and Capital Deployment - GPN generated operating cash flows of $818 million in the second quarter, up from $736.9 million a year ago [6] - The company repurchased shares worth $691.1 million in the first half of 2025 [9] - A quarterly dividend of 25 cents per share was declared, payable on September 26, 2025 [9] 2025 Outlook - GPN reaffirmed its 2025 guidance, expecting adjusted net revenue growth of 5% to 6% on a constant currency basis [10] - Adjusted EPS growth is anticipated to be between 10% and 11% in 2025 [10] - The company expects to convert nearly 90% of adjusted net income into adjusted free cash flow [10] - An increase of more than 50 basis points in the annual adjusted operating margin is also expected [10]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. Growth ...

Iconic brand joins growing roster of Nuvei merchants scaling globally from Hong Kong Nuvei is accelerating the business of clients around the world. Nuvei's modular, flexible and scalable technology allows leading companies to accept next-gen payments, offer all payout options and benefit from card issuing, banking, risk and fraud management services. Connecting businesses to their customers in more than 200 markets, with local acquiring in 50 markets, 150 currencies and 720 alternative payment methods, Nuv ...

Financial Data and Key Metrics Changes - Company reported record revenue of $19.1 million, up 33% year-over-year, with gross margins improving by 870 basis points to 61.6% [5][13] - Adjusted EBITDA doubled to $4.5 million, a 102% increase from the same quarter last year, and net income nearly doubled to $1.4 million, up 99% year-over-year [5][15] - Total operating expenses increased by 38.3% to $10.3 million, with SG&A rising 35.4% to $7.2 million [14] Business Line Data and Key Metrics Changes - Patient affordability business revenue grew 190% year-over-year to $7.75 million, accounting for 40.6% of total revenue, up from 18.7% in the same period last year [5][14] - Plasma compensation business revenue was $10.7 million, down 4.7% year-over-year but up 14.2% sequentially [7][8] Market Data and Key Metrics Changes - Company ended the quarter with 607 plasma centers, having onboarded 123 of the 132 awarded centers, achieving approximately 50% market share [8][9] - The company expects to onboard an additional 10 to 13 centers in the second half of the year [8] Company Strategy and Development Direction - Company plans to open a new patient services contact center to increase support capacity fourfold, addressing growing demand [6] - Introduction of a software as a service engagement platform at the International Plasma Protein Congress, indicating a shift towards becoming a broader technology provider [10] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the business prospects for the remainder of the year and into 2026, despite headwinds in the plasma business [12][17] - The company anticipates a return to organic growth in plasma collection starting in 2026 as the collection cycle improves [9] Other Important Information - Company raised its revenue guidance for 2025 to a range of $76.5 million to $78.5 million, reflecting year-over-year growth of 32.7% at the midpoint [17] - Expects net income for the year to be between $6 million and $7 million, or $0.10 to $0.12 per diluted share [18] Q&A Session Summary Question: Can you touch on the 30 to 40 programs expected to onboard in pharma? - Response indicated a mix of new clients and additional programs from existing clients, approximately fifty-fifty [22][23] Question: On the plasma side, does the expected addition of centers include the nine onboarded after June 30? - Response confirmed that it includes the nine centers [25] Question: Update on the donor management system timeline? - Response indicated targeting approval by the end of the year [26][28] Question: How does the average revenue of new centers compare to existing business? - Response stated that new centers are expected to be in line with existing averages [33] Question: What strategies are in place to retain donors from closing centers? - Response explained that donors will be directed to nearby centers, ensuring retention [35][36] Question: Breakdown of revenue within pharma? - Response clarified that revenue comes from program setup fees, monthly management fees, and various transactional fees [39][40] Question: Should the increase in revenue per pharma program be interpreted as a shift towards more specialty programs? - Response indicated that while there is a concentration on specialty products, the increase is also due to additional services offered [48][49]